Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
pubmed:
15
4
2021
medline:
15
4
2021
entrez:
14
4
2021
Statut:
epublish
Résumé
A diverse portfolio of SARS-CoV-2 vaccine candidates is needed to combat the evolving COVID-19 pandemic. Here, we developed a subunit nanovaccine by conjugating SARS-CoV-2 Spike protein receptor binding domain (RBD) to the surface of oxidation-sensitive polymersomes. We evaluated the humoral and cellular responses of mice immunized with these surface-decorated polymersomes (RBD
Identifiants
pubmed: 33851166
doi: 10.1101/2021.04.08.438884
pmc: PMC8043456
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA014599
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007281
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007090
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA253248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219304
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007605
Pays : United States
Organisme : NCI NIH HHS
ID : F30 CA221250
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Commentaires et corrections
Type : UpdateIn
Déclaration de conflit d'intérêts
COMPETING INTERESTS M.A.S. and J.A.H. have patents related to the polymersome technology and interests in LantaBio, which has licensed those patents.